Fred W. Manak
Nessuna posizione attualmente
Profilo
Fred W.
Manak held former positions as Executive Director-Trade & Pricing at Amgen, Inc., Vice President-Reimbursement at Onyx Pharmaceuticals, Inc., Vice President-Market Access at InterMune, Inc., and Vice President-Access & Reimbursement at ACADIA Pharmaceuticals, Inc. He obtained an undergraduate degree from Muhlenberg College.
Precedenti posizioni note di Fred W. Manak
Società | Posizione | Fine |
---|---|---|
INTERMUNE INC | Corporate Officer/Principal | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - |
AMGEN INC. | Corporate Officer/Principal | - |
ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Formazione di Fred W. Manak
Muhlenberg College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
ACADIA PHARMACEUTICALS INC. | Health Technology |
AMGEN INC. | Health Technology |
Aziende private | 2 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Fred W. Manak